Position in NVS
as of Jun 30, 2026
· filed Aug 4, 2026
Position Value
$441,323
-$1,804 QoQ
Shares Held
2,816
-2.9% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.20%
of 13F equity value
Holder Rank
#947
of 1,602 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Rossby Financial, LCC holds $8,931,662 across 15 Drug Manufacturers - General names. NVS ranks #5 (4.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
2,376 | $2,849,845 | |
| 2 | JNJ |
Johnson & Johnson
|
8,159 | $2,072,141 | |
| 3 | MRK |
Merck & Co., Inc.
|
9,768 | $1,255,188 | |
| 4 | ABBV |
AbbVie Inc.
|
3,665 | $922,260 | |
| 5 | NVS |
Novartis AG
This page
|
2,816 | $441,323 | |
| 6 | AZN |
Astrazeneca PLC
|
1,904 | $361,036 | |
| 7 | AMGN |
Amgen Inc
|
786 | $284,626 | |
| 8 | PFE |
Pfizer Inc
|
11,140 | $268,251 |
All Filings in NVS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $441,323 | 2,816 | Shares | Sole | 2026-08-04 | |
| 2026-03-31 | $443,127 | 2,901 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $375,006 | 2,720 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $349,197 | 2,723 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $322,370 | 2,664 | Shares | Sole | 2025-08-01 | |
| 2025-03-31 | $285,946 | 2,565 | Shares | Sole | 2025-04-28 | |
| No filing history on record for this holder in this stock. | ||||||